BNF for Children 2011-2012

710 Appendix 1: Interactions BNFC 2011–2012Appendix 1: InteractionsMoclobemide (continued). Sympathomimetics: risk of hypertensive crisis whenmoclobemide given with .sympathomimeticsUlcer-healing Drugs: plasma concentration of moclobemideincreased by cimetidine (halve dose ofmoclobemide)ModafinilAntiepileptics: modafinil possibly increases plasmaconcentration of phenytoin. Ciclosporin: modafinil reduces plasma concentration of.ciclosporin. Oestrogens: modafinil accelerates metabolism of.oestrogens (reduced contraceptive effect—seep. 398)Moexipril see ACE InhibitorsMometasone see CorticosteroidsMonobactams see AztreonamMontelukast see Leukotriene Receptor AntagonistsMorphine see Opioid AnalgesicsMoxifloxacin see QuinolonesMoxisylyteACE Inhibitors: enhanced hypotensive effect whenmoxisylyte given with ACE inhibitorsAdrenergic Neurone Blockers: enhanced hypotensiveeffect when moxisylyte given with adrenergicneurone blockers. Alpha-blockers: possible severe postural hypotensionwhen moxisylyte given with .alpha-blockersAngiotensin-II Receptor Antagonists: enhancedhypotensive effect when moxisylyte given withangiotensin-II receptor antagonists. Beta-blockers: possible severe postural hypotensionwhen moxisylyte given with .beta-blockersCalcium-channel Blockers: enhanced hypotensiveeffect when moxisylyte given with calcium-channelblockersClonidine: enhanced hypotensive effect when moxisylytegiven with clonidineDiazoxide: enhanced hypotensive effect when moxisylytegiven with diazoxideDiuretics: enhanced hypotensive effect when moxisylytegiven with diureticsMethyldopa: enhanced hypotensive effect when moxisylytegiven with methyldopaMoxonidine: enhanced hypotensive effect when moxisylytegiven with moxonidineNitrates: enhanced hypotensive effect when moxisylytegiven with nitratesVasodilator Antihypertensives: enhanced hypotensiveeffect when moxisylyte given with hydralazine,minoxidil or sodium nitroprussideMoxonidineACE Inhibitors: enhanced hypotensive effect whenmoxonidine given with ACE inhibitorsAdrenergic Neurone Blockers: enhanced hypotensiveeffect when moxonidine given with adrenergicneurone blockersAlcohol: enhanced hypotensive effect when moxonidinegiven with alcoholAldesleukin: enhanced hypotensive effect when moxonidinegiven with aldesleukinAlpha-blockers: enhanced hypotensive effect whenmoxonidine given with alpha-blockersAnaesthetics, General: enhanced hypotensive effectwhen moxonidine given with general anaestheticsAnalgesics: hypotensive effect of moxonidine antagonisedby NSAIDsAngiotensin-II Receptor Antagonists: enhancedhypotensive effect when moxonidine given withangiotensin-II receptor antagonistsAntidepressants: enhanced hypotensive effect whenmoxonidine given with MAOIs; hypotensive effect ofmoxonidine possibly antagonised by tricyclics (manufacturerof moxonidine advises avoid concomitantuse)Antipsychotics: enhanced hypotensive effect whenmoxonidine given with phenothiazinesMoxonidine (continued)Anxiolytics and Hypnotics: enhanced hypotensiveeffect when moxonidine given with anxiolytics andhypnotics; sedative effects possibly increased whenmoxonidine given with benzodiazepinesBeta-blockers: enhanced hypotensive effect whenmoxonidine given with beta-blockersCalcium-channel Blockers: enhanced hypotensiveeffect when moxonidine given with calcium-channelblockersClonidine: enhanced hypotensive effect when moxonidinegiven with clonidineCorticosteroids: hypotensive effect of moxonidineantagonised by corticosteroidsDiazoxide: enhanced hypotensive effect when moxonidinegiven with diazoxideDiuretics: enhanced hypotensive effect when moxonidinegiven with diureticsDopaminergics: enhanced hypotensive effect whenmoxonidine given with levodopaMethyldopa: enhanced hypotensive effect when moxonidinegiven with methyldopaMoxisylyte: enhanced hypotensive effect when moxonidinegiven with moxisylyteMuscle Relaxants: enhanced hypotensive effect whenmoxonidine given with baclofen or tizanidineNitrates: enhanced hypotensive effect when moxonidinegiven with nitratesOestrogens: hypotensive effect of moxonidine antagonisedby oestrogensProstaglandins: enhanced hypotensive effect whenmoxonidine given with alprostadilVasodilator Antihypertensives: enhanced hypotensiveeffect when moxonidine given with hydralazine,minoxidil or sodium nitroprussideMuscle RelaxantsACE Inhibitors: enhanced hypotensive effect whenbaclofen or tizanidine given with ACE inhibitorsAdrenergic Neurone Blockers: enhanced hypotensiveeffect when baclofen or tizanidine given with adrenergicneurone blockersAlcohol: increased sedative effect when baclofen,methocarbamol or tizanidine given with alcoholAlpha-blockers: enhanced hypotensive effect whenbaclofen or tizanidine given with alpha-blockers. Anaesthetics, General: effects of atracurium enhancedby ketamine; increased risk of myocardial depressionand bradycardia when suxamethonium given with.propofol; effects of non-depolarising musclerelaxants and suxamethonium enhanced by volatileliquid general anaestheticsAnalgesics: excretion of baclofen possibly reduced byNSAIDs (increased risk of toxicity); excretion ofbaclofen reduced by ibuprofen (increased risk oftoxicity); increased sedative effect when baclofengiven with fentanyl or morphineAngiotensin-II Receptor Antagonists: enhancedhypotensive effect when baclofen or tizanidine givenwith angiotensin-II receptor antagonistsAnti-arrhythmics: neuromuscular blockade enhancedand prolonged when suxamethonium given withlidocaine. Antibacterials: effects of non-depolarising musclerelaxants and suxamethonium enhanced by piperacillin;plasma concentration of tizanidine increasedby .ciprofloxacin (increased risk of toxicity)—avoidconcomitant use; plasma concentration of tizanidinepossibly increased by norfloxacin (increased risk oftoxicity); effects of non-depolarising musclerelaxants and suxamethonium enhanced by.aminoglycosides; effects of non-depolarising musclerelaxants and suxamethonium enhanced by.clindamycin; effects of non-depolarising musclerelaxants and suxamethonium enhanced by.polymyxins; effects of suxamethonium enhanced by.vancomycin. Antidepressants: plasma concentration of tizanidineincreased by .fluvoxamine (increased risk of toxicity)—avoidconcomitant use; effects of suxa-